In Stock

• Cagrilintide (AM833) is an investigational, long-acting amylin analog developed by Novo Nordisk for weight loss, mimicking the satiety hormone amylin to reduce appetite, slow stomach emptying, and promote feelings of fullness, often in combination with semaglutide (as CagriSema) for substantial weight reduction in Phase 3 trials, showing promise as a next-generation obesity treatment with a distinct mechanism from GLP-1s.